Country: United States
Language: English
Source: NLM (National Library of Medicine)
ZIDOVUDINE (UNII: 4B9XT59T7S) (ZIDOVUDINE - UNII:4B9XT59T7S)
Cipla Ltd.
ZIDOVUDINE
ZIDOVUDINE 300 mg
ORAL
PRESCRIPTION DRUG
Zidovudine, a nucleoside reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Zidovudine is indicated for the prevention of maternal-fetal HIV-1 transmission [see Dosage and Administration (2.3)]. The indication is based on a dosing regimen that included 3 components: - antepartum therapy of HIV-1 infected mothers - intrapartum therapy of HIV-1 infected mothers - post-partum therapy of HIV-1 exposed neonate Points to consider prior to initiating Zidovudine in pregnant women for the prevention of maternal-fetal HIV-1 transmission include: - In most cases, Zidovudine for prevention of maternal-fetal HIV-1 transmission should be given in combination with other antiretroviral drugs. - Prevention of HIV-1 transmission in women who have received Zidovudine for a prolonged period before pregnancy has not been evaluated. - Because the fetus is most susceptible to the potential teratogenic effects of drugs during the first 10 weeks of ges
Zidovudine tablets USP, 300 mg are white, circular, biconvex , film coated tablets with '300' debossed on one side and 'ZVR' on other side Zidovudine tablets USP,300 mg are available as follows : Bottle of 60 tablets (NDC 53104- 0101-2) Bottle of 1000 tablets (NDC 53104 - 0101-6) Unit dose boxes of 100 tablets (NDC 53104 – 0101 -9) Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature.]
Abbreviated New Drug Application
ZIDOVUDINE- ZIDOVUDINE TABLET, FILM COATED CIPLA LTD. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ZIDOVUDINE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ZIDOVUDINE TABLETS. ZIDOVUDINE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1987 WARNING: RISK OF HEMATOLOGICAL TOXICITY, MYOPATHY, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ HEMATOLOGIC TOXICITY INCLUDING NEUTROPENIA AND SEVERE ANEMIA HAVE BEEN ASSOCIATED WITH THE USE OF ZIDOVUDINE. (5.1) SYMPTOMATIC MYOPATHY ASSOCIATED WITH PROLONGED USE OF ZIDOVUDINE. (5.3) LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, INCLUDING FATAL CASES, HAVE BEEN REPORTED WITH THE USE OF NUCLEOSIDE ANALOGUES INCLUDING ZIDOVUDINE. SUSPEND TREATMENT IF CLINICAL OR LABORATORY FINDINGS SUGGESTIVE OF LACTIC ACIDOSIS OR PRONOUNCED HEPATOTOXICITY OCCUR. (5.4) INDICATIONS AND USAGE Zidovudine is a nucleoside analogue reverse transcriptase inhibitor indicated for: Treatment of Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral agents. (1.1) Prevention of maternal-fetal HIV-1 transmission. (1.2) DOSAGE AND ADMINISTRATION ● Treatment of HIV-1 infection: Adults: Recommended oral dosage is 300 mg twice a day with other antiretroviral agents. (2.1) Pediatric patients (aged 4 weeks to less than 18 years): Dosage should be calculated based on body weight not to exceed adult dose. (2.2) ● Prevention of maternal-fetal HIV-1 transmission: Specific dosage instructions for mother and infant. (2.3) ● Patients with severe anemia and/or neutropenia: Dosage interruption may be necessary. (2.4) ● Renal impairment: Recommended oral dosage in hemodialysis or peritoneal dialysis or in patients with creatinine clearance (CrCl) less than 15 mL per minute is 100 mg every 6 to 8 hours. (2.5) DOSAGE FORMS AND STRENGTHS Tablets: 300 mg (3) CONTRAINDICATIONS Hypersensitivity to zidovudine or any of the Read the complete document